PLASMA AND URINARY LEVELS OF TRIAMTERENE AND CERTAIN METABOLITES AFTER ORAL-ADMINISTRATION TO MAN

被引:34
作者
GUNDERTREMY, U [1 ]
VONKENNE, D [1 ]
WEBER, E [1 ]
GEISSLER, HE [1 ]
GREBIAN, B [1 ]
MUTSCHLER, E [1 ]
机构
[1] UNIV FRANKFURT,INST PHARMACOL,DEPT BIOCHEM & PHARM,D-6000 FRANKFURT 70,FED REP GER
关键词
diuretic effects; pharmacokinetics; triamterene;
D O I
10.1007/BF00644964
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
The plasma and urinary levels of triamterene and two metabolites were measured using a specific method of analysis. Urinary excretion was completed after 48 h, which permitted a rough estimate of its half-life as longer than two hours. The areas under the curve were 672.5±160.3 and 1.311.3±399.1 μg/ml × h after the triameterene 150 mg and 300 mg p.o., respectively and correspondingly 4.2±1.4% and 3.7±0.6% of the dose were excreted as unchanged drug. The principal metabolite of triamterene found was the sulfate conjugate. The area under the curve of this metabolite amounted to 6.672±2.120 and 11.941±5.005 μg/ml × h after the of 150 mg and 300 mg triamterene doses, respectively. The urinary excretion of the metabolite varied between 25.0±4.0% and 17.5±3.5% of the dose after either dose. In healthy subjects an effect on sodium excretion was observed after a dose of 150 mg, whereas the potassium-retaining effect was observed only after the dose of 300 mg. © 1979 Springer-Verlag.
引用
收藏
页码:39 / 44
页数:6
相关论文
共 15 条
[1]  
ANDRASCH H, 1971, Z GASTROENTEROL, V9, P240
[2]  
BABA W I, 1962, Br Med J, V2, P756
[3]  
BADINAND A, 1964, J MED LYON, V1047, P19
[4]  
DAYTON PG, 1976, PHARMACOLOGIST, V18, P153
[5]  
DETTLI L, 1965, ARZNEI-FORSCHUNG, V15, P1162
[6]  
GREBIAN B, 1976, ARZNEIMITTEL-FORSCH, V26, P2125
[7]  
GREEFF K, 1975, ARZNEIMITTEL-FORSCH, V25, P1766
[8]  
GUNDERTREMY U, 1977, NAUNYNSCHMIEDEBER S2, V297, pR9
[9]  
LASSEN JB, 1963, ACTA PHARMACOL TOX, V20, P309
[10]  
LEHMANN K, 1965, ARZNEI-FORSCHUNG, V15, P812